TW520362B - Substituted pyrimidine compounds and pharmaceutical composition comprising same - Google Patents

Substituted pyrimidine compounds and pharmaceutical composition comprising same Download PDF

Info

Publication number: TW520362B
Authority: TW; Taiwan
Prior art keywords: amino; fluorophenyl; pyridyl; group; phenyl
Prior art date: 1996-12-05

Application number

TW086118244A

Other languages

English (en)

Chinese (zh)

Inventor

Ulrike D Spohr

Michael J Malone

Nathan B Mantlo

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-05

Filing date

1997-12-04

Publication date

2003-02-11

1997-12-04 Application filed by Amgen Inc filed Critical Amgen Inc

2003-02-11 Application granted granted Critical

2003-02-11 Publication of TW520362B publication Critical patent/TW520362B/zh

Links

239000008194 pharmaceutical composition Chemical class 0.000 title claims abstract description 15
150000003230 pyrimidines Chemical class 0.000 title description 6
150000001875 compounds Chemical class 0.000 claims abstract description 149
238000000034 method Methods 0.000 claims abstract description 78
201000010099 disease Diseases 0.000 claims abstract description 38
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 38
150000003839 salts Chemical class 0.000 claims abstract description 23
238000011282 treatment Methods 0.000 claims abstract description 18
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 11
206010061218 Inflammation Diseases 0.000 claims abstract description 6
230000004054 inflammatory process Effects 0.000 claims abstract description 6
-1 Phenylthiomethyl Chemical group 0.000 claims description 746
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 256
125000000217 alkyl group Chemical group 0.000 claims description 203
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 164
125000003282 alkyl amino group Chemical group 0.000 claims description 110
150000001412 amines Chemical class 0.000 claims description 101
125000003277 amino group Chemical group 0.000 claims description 96
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 87
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 79
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 76
239000000203 mixture Substances 0.000 claims description 65
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 59
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 43
125000004076 pyridyl group Chemical group 0.000 claims description 40
125000001207 fluorophenyl group Chemical group 0.000 claims description 23
229910052736 halogen Inorganic materials 0.000 claims description 18
150000002367 halogens Chemical class 0.000 claims description 18
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
238000006467 substitution reaction Methods 0.000 claims description 14
229960004666 glucagon Drugs 0.000 claims description 13
230000000694 effects Effects 0.000 claims description 12
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 11
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 10
102000051325 Glucagon Human genes 0.000 claims description 10
108060003199 Glucagon Proteins 0.000 claims description 10
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 10
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 10
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 10
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
206010040070 Septic Shock Diseases 0.000 claims description 9
VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 9
241000701022 Cytomegalovirus Species 0.000 claims description 8
206010006895 Cachexia Diseases 0.000 claims description 7
206010028289 Muscle atrophy Diseases 0.000 claims description 7
230000006378 damage Effects 0.000 claims description 7
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 7
206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 6
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 6
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 6
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 6
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 6
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 6
206010063837 Reperfusion injury Diseases 0.000 claims description 6
208000006011 Stroke Diseases 0.000 claims description 6
230000001154 acute effect Effects 0.000 claims description 6
201000008482 osteoarthritis Diseases 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 6
208000011580 syndromic disease Diseases 0.000 claims description 6
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
206010009900 Colitis ulcerative Diseases 0.000 claims description 5
206010020751 Hypersensitivity Diseases 0.000 claims description 5
206010040047 Sepsis Diseases 0.000 claims description 5
208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
241000700605 Viruses Species 0.000 claims description 5
208000006673 asthma Diseases 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 5
239000008280 blood Substances 0.000 claims description 5
208000019664 bone resorption disease Diseases 0.000 claims description 5
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
201000006417 multiple sclerosis Diseases 0.000 claims description 5
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
125000006308 propyl amino group Chemical group 0.000 claims description 5
150000003180 prostaglandins Chemical class 0.000 claims description 5
230000036303 septic shock Effects 0.000 claims description 5
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
206010012442 Dermatitis contact Diseases 0.000 claims description 4
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
208000001132 Osteoporosis Diseases 0.000 claims description 4
206010037660 Pyrexia Diseases 0.000 claims description 4
206010039085 Rhinitis allergic Diseases 0.000 claims description 4
206010044248 Toxic shock syndrome Diseases 0.000 claims description 4
231100000650 Toxic shock syndrome Toxicity 0.000 claims description 4
201000010105 allergic rhinitis Diseases 0.000 claims description 4
230000007815 allergy Effects 0.000 claims description 4
206010003246 arthritis Diseases 0.000 claims description 4
208000010247 contact dermatitis Diseases 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
230000000302 ischemic effect Effects 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
230000017702 response to host Effects 0.000 claims description 4
241000701161 unidentified adenovirus Species 0.000 claims description 4
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
208000024827 Alzheimer disease Diseases 0.000 claims description 3
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 3
208000034578 Multiple myelomas Diseases 0.000 claims description 3
206010033557 Palpitations Diseases 0.000 claims description 3
206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
239000012528 membrane Substances 0.000 claims description 3
PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical group FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 claims description 3
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 3
208000010125 myocardial infarction Diseases 0.000 claims description 3
125000004344 phenylpropyl group Chemical group 0.000 claims description 3
241001529453 unidentified herpesvirus Species 0.000 claims description 3
YJVKLLJCUMQBHN-UHFFFAOYSA-N 2-pyridin-2-ylpyrimidine Chemical compound N1=CC=CC=C1C1=NC=CC=N1 YJVKLLJCUMQBHN-UHFFFAOYSA-N 0.000 claims description 2
LNPMZQXEPNWCMG-UHFFFAOYSA-N 4-(2-aminoethyl)aniline Chemical compound NCCC1=CC=C(N)C=C1 LNPMZQXEPNWCMG-UHFFFAOYSA-N 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 claims description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
208000026935 allergic disease Diseases 0.000 claims description 2
239000005557 antagonist Substances 0.000 claims description 2
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
230000002490 cerebral effect Effects 0.000 claims description 2
229960005181 morphine Drugs 0.000 claims description 2
PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 1
VHJKDOLGYMULOP-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1Cl VHJKDOLGYMULOP-UHFFFAOYSA-N 0.000 claims 1
125000003070 2-(2-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
DLUYDWMBZSEZCU-UHFFFAOYSA-N 2-[(2,6-dichlorophenyl)methyl]-5-(4-fluorophenyl)-4-pyridin-4-ylpyrimidine Chemical compound C1=CC(F)=CC=C1C(C(=N1)C=2C=CN=CC=2)=CN=C1CC1=C(Cl)C=CC=C1Cl DLUYDWMBZSEZCU-UHFFFAOYSA-N 0.000 claims 1
125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
AYUVXKSTUTVAMO-UHFFFAOYSA-N 5-(4-fluorophenyl)-2-(phenylsulfanylmethyl)-4-pyridin-4-ylpyrimidine Chemical compound C1=CC(F)=CC=C1C(C(=N1)C=2C=CN=CC=2)=CN=C1CSC1=CC=CC=C1 AYUVXKSTUTVAMO-UHFFFAOYSA-N 0.000 claims 1
CWEMLTMVMPIHTR-UHFFFAOYSA-N 5-(4-fluorophenyl)-n-(2-methoxyphenyl)-4-pyridin-4-ylpyrimidin-2-amine Chemical compound COC1=CC=CC=C1NC(N=C1C=2C=CN=CC=2)=NC=C1C1=CC=C(F)C=C1 CWEMLTMVMPIHTR-UHFFFAOYSA-N 0.000 claims 1
WAUSKYGFULPCPY-UHFFFAOYSA-N 5-(4-fluorophenyl)-n-(2-phenylethyl)-4-pyridin-4-ylpyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1C(C(=N1)C=2C=CN=CC=2)=CN=C1NCCC1=CC=CC=C1 WAUSKYGFULPCPY-UHFFFAOYSA-N 0.000 claims 1
206010003210 Arteriosclerosis Diseases 0.000 claims 1
208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
206010014978 Epidemic pleurodynia Diseases 0.000 claims 1
240000005708 Eugenia stipitata Species 0.000 claims 1
235000006149 Eugenia stipitata Nutrition 0.000 claims 1
206010020772 Hypertension Diseases 0.000 claims 1
GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 claims 1
208000034189 Sclerosis Diseases 0.000 claims 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims 1
229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 39
102000004890 Interleukin-8 Human genes 0.000 abstract description 17
108090001007 Interleukin-8 Proteins 0.000 abstract description 17
108090001005 Interleukin-6 Proteins 0.000 abstract description 14
239000000543 intermediate Substances 0.000 abstract description 10
208000002193 Pain Diseases 0.000 abstract description 6
230000001404 mediated effect Effects 0.000 abstract description 5
229940002612 prodrug Drugs 0.000 abstract description 3
239000000651 prodrug Substances 0.000 abstract description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 2
150000003222 pyridines Chemical class 0.000 abstract description 2
238000011321 prophylaxis Methods 0.000 abstract 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
238000011049 filling Methods 0.000 description 169
125000001424 substituent group Chemical group 0.000 description 121
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 120
125000003545 alkoxy group Chemical group 0.000 description 118
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 114
125000003118 aryl group Chemical group 0.000 description 102
230000002079 cooperative effect Effects 0.000 description 97
125000001072 heteroaryl group Chemical group 0.000 description 92
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
125000005843 halogen group Chemical group 0.000 description 80
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 79
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 72
238000005481 NMR spectroscopy Methods 0.000 description 72
125000000623 heterocyclic group Chemical group 0.000 description 71
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 65
125000004414 alkyl thio group Chemical group 0.000 description 61
238000006243 chemical reaction Methods 0.000 description 56
125000002887 hydroxy group Chemical group [H]O* 0.000 description 56
102100040247 Tumor necrosis factor Human genes 0.000 description 51
125000004093 cyano group Chemical group *C#N 0.000 description 51
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 50
239000000243 solution Substances 0.000 description 50
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 49
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 44
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 40
238000002360 preparation method Methods 0.000 description 39
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 38
229910052739 hydrogen Inorganic materials 0.000 description 38
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 36
239000001257 hydrogen Substances 0.000 description 36
210000004027 cell Anatomy 0.000 description 35
UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 32
125000005422 alkyl sulfonamido group Chemical group 0.000 description 31
101150041968 CDC13 gene Proteins 0.000 description 30
239000002585 base Substances 0.000 description 30
NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 30
125000004429 atom Chemical group 0.000 description 29
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 29
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 29
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 26
239000002253 acid Substances 0.000 description 24
238000001704 evaporation Methods 0.000 description 24
230000008020 evaporation Effects 0.000 description 24
238000012360 testing method Methods 0.000 description 24
238000003556 assay Methods 0.000 description 23
125000000753 cycloalkyl group Chemical group 0.000 description 23
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 22
125000001188 haloalkyl group Chemical group 0.000 description 22
229910052760 oxygen Inorganic materials 0.000 description 20
125000004663 dialkyl amino group Chemical group 0.000 description 19
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 19
125000004435 hydrogen atom Chemical group [H]* 0.000 description 19
239000001301 oxygen Substances 0.000 description 19
229910000272 alkali metal oxide Inorganic materials 0.000 description 18
125000004432 carbon atom Chemical group C* 0.000 description 18
238000010992 reflux Methods 0.000 description 18
108010002352 Interleukin-1 Proteins 0.000 description 17
102000000589 Interleukin-1 Human genes 0.000 description 17
125000003710 aryl alkyl group Chemical group 0.000 description 17
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 17
239000007787 solid Substances 0.000 description 17
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
239000000047 product Substances 0.000 description 16
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 15
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 14
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
125000004466 alkoxycarbonylamino group Chemical group 0.000 description 14
229910052757 nitrogen Inorganic materials 0.000 description 14
150000003254 radicals Chemical class 0.000 description 14
239000000741 silica gel Substances 0.000 description 14
229910002027 silica gel Inorganic materials 0.000 description 14
102000004889 Interleukin-6 Human genes 0.000 description 13
125000004390 alkyl sulfonyl group Chemical group 0.000 description 13
229940100601 interleukin-6 Drugs 0.000 description 13
239000003921 oil Substances 0.000 description 13
235000019198 oils Nutrition 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
125000004644 alkyl sulfinyl group Chemical group 0.000 description 12
239000000460 chlorine Chemical group 0.000 description 12
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 12
210000001616 monocyte Anatomy 0.000 description 12
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 11
102000004127 Cytokines Human genes 0.000 description 11
108090000695 Cytokines Proteins 0.000 description 11
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 11
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 11
239000002904 solvent Substances 0.000 description 11
239000000725 suspension Substances 0.000 description 11
125000004149 thio group Chemical group *S* 0.000 description 11
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
238000004440 column chromatography Methods 0.000 description 10
239000002158 endotoxin Substances 0.000 description 10
229920006008 lipopolysaccharide Polymers 0.000 description 10
239000000463 material Substances 0.000 description 10
239000002609 medium Substances 0.000 description 10
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 10
125000006239 protecting group Chemical group 0.000 description 10
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
230000027455 binding Effects 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
229920006395 saturated elastomer Polymers 0.000 description 9
229910052717 sulfur Inorganic materials 0.000 description 9
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 9
101150010802 CVC2 gene Proteins 0.000 description 8
241000700159 Rattus Species 0.000 description 8
125000000304 alkynyl group Chemical group 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
230000000875 corresponding effect Effects 0.000 description 8
238000003818 flash chromatography Methods 0.000 description 8
230000002757 inflammatory effect Effects 0.000 description 8
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
238000010898 silica gel chromatography Methods 0.000 description 8
239000007858 starting material Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
125000004453 alkoxycarbonyl group Chemical group 0.000 description 7
150000003973 alkyl amines Chemical class 0.000 description 7
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
125000004122 cyclic group Chemical group 0.000 description 7
230000018044 dehydration Effects 0.000 description 7
238000006297 dehydration reaction Methods 0.000 description 7
238000010586 diagram Methods 0.000 description 7
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 7
238000000605 extraction Methods 0.000 description 7
KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 7
150000007857 hydrazones Chemical class 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
210000000440 neutrophil Anatomy 0.000 description 7
235000017557 sodium bicarbonate Nutrition 0.000 description 7
229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 7
125000003944 tolyl group Chemical group 0.000 description 7
238000005160 1H NMR spectroscopy Methods 0.000 description 6
DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 6
BJLFRYUEDOKXRO-UHFFFAOYSA-N 2-pyridin-4-ylpyrimidine Chemical compound N1=CC=CN=C1C1=CC=NC=C1 BJLFRYUEDOKXRO-UHFFFAOYSA-N 0.000 description 6
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 6
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
239000012091 fetal bovine serum Substances 0.000 description 6
239000007789 gas Substances 0.000 description 6
239000008103 glucose Substances 0.000 description 6
229960004198 guanidine Drugs 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
150000002576 ketones Chemical class 0.000 description 6
239000007788 liquid Substances 0.000 description 6
WGYKZJWCGVVSQN-UHFFFAOYSA-N mono-n-propyl amine Natural products CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 6
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 6
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
IAJINJSFYTZPEJ-UHFFFAOYSA-N 1h-pyrimidin-3-ium-2-one;chloride Chemical compound Cl.O=C1N=CC=CN1 IAJINJSFYTZPEJ-UHFFFAOYSA-N 0.000 description 5
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 5
SVBLNCJETIXIPV-UHFFFAOYSA-N 2-methyl-3-phenylpropan-1-amine Chemical compound NCC(C)CC1=CC=CC=C1 SVBLNCJETIXIPV-UHFFFAOYSA-N 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 5
206010030113 Oedema Diseases 0.000 description 5
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 5
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 5
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
229940024606 amino acid Drugs 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
229940114079 arachidonic acid Drugs 0.000 description 5
235000021342 arachidonic acid Nutrition 0.000 description 5
229910052786 argon Inorganic materials 0.000 description 5
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 5
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
239000004202 carbamide Substances 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
239000012043 crude product Substances 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 5
239000003814 drug Substances 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000006722 reduction reaction Methods 0.000 description 5
239000011734 sodium Substances 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000011593 sulfur Substances 0.000 description 5
150000003573 thiols Chemical class 0.000 description 5
229910052727 yttrium Inorganic materials 0.000 description 5
WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 4
125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 4
LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 4
YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
201000001320 Atherosclerosis Diseases 0.000 description 4
125000004648 C2-C8 alkenyl group Chemical group 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
201000005569 Gout Diseases 0.000 description 4
206010018634 Gouty Arthritis Diseases 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 4
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
150000001335 aliphatic alkanes Chemical class 0.000 description 4
125000003342 alkenyl group Chemical group 0.000 description 4
150000001409 amidines Chemical class 0.000 description 4
239000000908 ammonium hydroxide Substances 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
230000003078 antioxidant effect Effects 0.000 description 4
125000005140 aralkylsulfonyl group Chemical group 0.000 description 4
125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 4
125000002102 aryl alkyloxo group Chemical group 0.000 description 4
239000012131 assay buffer Substances 0.000 description 4
150000001540 azides Chemical class 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
229910052794 bromium Inorganic materials 0.000 description 4
239000000872 buffer Substances 0.000 description 4
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
125000004112 carboxyamino group Chemical group [H]OC(=O)N([H])[*] 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical compound ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 4
125000004188 dichlorophenyl group Chemical group 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000011737 fluorine Chemical group 0.000 description 4
229910052731 fluorine Inorganic materials 0.000 description 4
239000012458 free base Substances 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
239000011777 magnesium Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
125000000714 pyrimidinyl group Chemical group 0.000 description 4
239000000376 reactant Substances 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
230000004044 response Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
239000012258 stirred mixture Substances 0.000 description 4
125000003107 substituted aryl group Chemical group 0.000 description 4
125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
125000003396 thiol group Chemical group [H]S* 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
238000005406 washing Methods 0.000 description 4
125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 3
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 3
LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
206010012335 Dependence Diseases 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108010063919 Glucagon Receptors Proteins 0.000 description 3
102100040890 Glucagon receptor Human genes 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
229930194542 Keto Natural products 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-Phenylalanine Natural products OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 3
208000000112 Myalgia Diseases 0.000 description 3
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
230000001464 adherent effect Effects 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
229910000147 aluminium phosphate Inorganic materials 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000004305 biphenyl Substances 0.000 description 3
235000010290 biphenyl Nutrition 0.000 description 3
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
235000010418 carrageenan Nutrition 0.000 description 3
239000000679 carrageenan Substances 0.000 description 3
229920001525 carrageenan Polymers 0.000 description 3
229940113118 carrageenan Drugs 0.000 description 3
125000000068 chlorophenyl group Chemical group 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
239000006260 foam Substances 0.000 description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
150000004820 halides Chemical class 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
125000004446 heteroarylalkyl group Chemical group 0.000 description 3
125000005842 heteroatom Chemical group 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
125000000468 ketone group Chemical group 0.000 description 3
239000010410 layer Substances 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
230000000269 nucleophilic effect Effects 0.000 description 3
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
125000003395 phenylethylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
239000006187 pill Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
229910052710 silicon Inorganic materials 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
125000004434 sulfur atom Chemical group 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
239000011975 tartaric acid Substances 0.000 description 3
235000002906 tartaric acid Nutrition 0.000 description 3
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 3
241000712461 unidentified influenza virus Species 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 3
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
ODCATTUUPYWMMI-DHZHZOJOSA-N (e)-3-(4-aminophenyl)-1-phenylprop-2-en-1-one Chemical compound C1=CC(N)=CC=C1\C=C\C(=O)C1=CC=CC=C1 ODCATTUUPYWMMI-DHZHZOJOSA-N 0.000 description 2
LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
JLIDRDJNLAWIKT-UHFFFAOYSA-N 1,2-dimethyl-3h-benzo[e]indole Chemical compound C1=CC=CC2=C(C(=C(C)N3)C)C3=CC=C21 JLIDRDJNLAWIKT-UHFFFAOYSA-N 0.000 description 2
IVSZLXZYQVIEFR-UHFFFAOYSA-N 1,3-Dimethylbenzene Natural products CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
RHWPOMMEZPJCJP-UHFFFAOYSA-N 2-(2-fluorophenyl)-4-(4-phenylpiperazin-1-yl)quinazoline Chemical compound FC1=CC=CC=C1C1=NC(N2CCN(CC2)C=2C=CC=CC=2)=C(C=CC=C2)C2=N1 RHWPOMMEZPJCJP-UHFFFAOYSA-N 0.000 description 2
JHQBLYITVCBGTO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C=C1 JHQBLYITVCBGTO-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical group CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
LLJRXVHJOJRCSM-UHFFFAOYSA-N 3-pyridin-4-yl-1H-indole Chemical group C=1NC2=CC=CC=C2C=1C1=CC=NC=C1 LLJRXVHJOJRCSM-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
QYHBYHLILDBRAT-UHFFFAOYSA-N 4-(4-benzylpiperazin-1-yl)-2-(2-fluorophenyl)quinazoline Chemical compound FC1=CC=CC=C1C1=NC(N2CCN(CC=3C=CC=CC=3)CC2)=C(C=CC=C2)C2=N1 QYHBYHLILDBRAT-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 2
125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
206010002198 Anaphylactic reaction Diseases 0.000 description 2
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
208000009386 Experimental Arthritis Diseases 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
239000012425 OXONE® Substances 0.000 description 2
241000282376 Panthera tigris Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
229910000831 Steel Inorganic materials 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
229910052769 Ytterbium Inorganic materials 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
125000001980 alanyl group Chemical group 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
125000004647 alkyl sulfenyl group Chemical group 0.000 description 2
125000004656 alkyl sulfonylamino group Chemical group 0.000 description 2
125000001118 alkylidene group Chemical group 0.000 description 2
125000006242 amine protecting group Chemical group 0.000 description 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
230000036783 anaphylactic response Effects 0.000 description 2
208000003455 anaphylaxis Diseases 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
125000004659 aryl alkyl thio group Chemical group 0.000 description 2
150000004646 arylidenes Chemical group 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
229940009098 aspartate Drugs 0.000 description 2
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
DULCUDSUACXJJC-UHFFFAOYSA-N benzeneacetic acid ethyl ester Natural products CCOC(=O)CC1=CC=CC=C1 DULCUDSUACXJJC-UHFFFAOYSA-N 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical class NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
125000000707 boryl group Chemical group B* 0.000 description 2
RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
125000006630 butoxycarbonylamino group Chemical group 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000013043 chemical agent Substances 0.000 description 2
150000001804 chlorine Chemical class 0.000 description 2
238000004891 communication Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
125000006286 dichlorobenzyl group Chemical group 0.000 description 2
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
JDZLOJYSBBLXQD-UHFFFAOYSA-N difluoromethylbenzene Chemical compound FC(F)C1=CC=CC=C1 JDZLOJYSBBLXQD-UHFFFAOYSA-N 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
238000004821 distillation Methods 0.000 description 2
CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 2
XVBZFXZNJAFCHL-UHFFFAOYSA-N ethyl 2-aminopyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(N)=C1 XVBZFXZNJAFCHL-UHFFFAOYSA-N 0.000 description 2
229940064982 ethylnicotinate Drugs 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000009229 glucose formation Effects 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
239000008187 granular material Substances 0.000 description 2
125000004475 heteroaralkyl group Chemical group 0.000 description 2
150000002391 heterocyclic compounds Chemical class 0.000 description 2
238000007327 hydrogenolysis reaction Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
239000005457 ice water Substances 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
230000018276 interleukin-1 production Effects 0.000 description 2
239000011630 iodine Substances 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 2
125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
125000002757 morpholinyl group Chemical group 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 2
239000012053 oil suspension Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
229910052762 osmium Inorganic materials 0.000 description 2
SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical group [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
229960005190 phenylalanine Drugs 0.000 description 2
229950010765 pivalate Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000007639 printing Methods 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
OKULHRWWYCFJAB-UHFFFAOYSA-N pyrimidine-4-carbaldehyde Chemical compound O=CC1=CC=NC=N1 OKULHRWWYCFJAB-UHFFFAOYSA-N 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000035939 shock Effects 0.000 description 2
238000006884 silylation reaction Methods 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
235000010288 sodium nitrite Nutrition 0.000 description 2
239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
239000002689 soil Substances 0.000 description 2
239000010959 steel Substances 0.000 description 2
239000001384 succinic acid Substances 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
238000006277 sulfonation reaction Methods 0.000 description 2
XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 2
210000002437 synoviocyte Anatomy 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
150000007944 thiolates Chemical class 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
229910052722 tritium Inorganic materials 0.000 description 2
230000006433 tumor necrosis factor production Effects 0.000 description 2
DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
229920002554 vinyl polymer Polymers 0.000 description 2
NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 2
QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
QITPYWCHGKOEAC-NSHDSACASA-N (2s)-2-n-ethyl-3-phenylpropane-1,2-diamine Chemical compound CCN[C@H](CN)CC1=CC=CC=C1 QITPYWCHGKOEAC-NSHDSACASA-N 0.000 description 1
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
PDKPRWFMRVBCOB-JLHYYAGUSA-N (e)-3-[4-(dimethylamino)phenyl]-1-phenylprop-2-en-1-one Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C(=O)C1=CC=CC=C1 PDKPRWFMRVBCOB-JLHYYAGUSA-N 0.000 description 1
GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
WAZWPWNJVULLRQ-UHFFFAOYSA-N 1,1-dimethyl-2-(3-phenylpropyl)hydrazine Chemical compound CN(C)NCCCC1=CC=CC=C1 WAZWPWNJVULLRQ-UHFFFAOYSA-N 0.000 description 1
XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 1
ZPQOPVIELGIULI-UHFFFAOYSA-N 1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1 ZPQOPVIELGIULI-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
VWUXTCLOJJEWNJ-UHFFFAOYSA-N 1-cyclohexyl-3-pyridin-4-ylprop-2-en-1-one Chemical compound C1CCCCC1C(=O)C=CC1=CC=NC=C1 VWUXTCLOJJEWNJ-UHFFFAOYSA-N 0.000 description 1
UQSSAUPVJWURAP-UHFFFAOYSA-N 1-ethyl-2-(3-phenylpropyl)hydrazine Chemical compound CCNNCCCC1=CC=CC=C1 UQSSAUPVJWURAP-UHFFFAOYSA-N 0.000 description 1
YFTNTMQKPLVKFQ-UHFFFAOYSA-N 1-methoxy-n,n-dimethylmethanamine Chemical compound COCN(C)C YFTNTMQKPLVKFQ-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical class CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
LNWWQYYLZVZXKS-UHFFFAOYSA-N 1-pyrrolidin-1-ylethanone Chemical class CC(=O)N1CCCC1 LNWWQYYLZVZXKS-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
WZJLGICGNMAUFC-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-fluorene Chemical compound C12=CC=CC=C2CC2=C1CCCC2 WZJLGICGNMAUFC-UHFFFAOYSA-N 0.000 description 1
GHZHWDWADLAOIQ-UHFFFAOYSA-N 2,3-bis(4-hydroxyphenyl)propionitrile Chemical compound C1=CC(O)=CC=C1CC(C#N)C1=CC=C(O)C=C1 GHZHWDWADLAOIQ-UHFFFAOYSA-N 0.000 description 1
CSJCEQXZVMIHRX-UHFFFAOYSA-N 2,3-dibenzyl-2,3-dihydroxybutanedioic acid Chemical compound C=1C=CC=CC=1CC(O)(C(O)=O)C(O)(C(=O)O)CC1=CC=CC=C1 CSJCEQXZVMIHRX-UHFFFAOYSA-N 0.000 description 1
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
OFIMNDTVWZPKIN-UHFFFAOYSA-N 2,6-dimethylpyridine-4-carbaldehyde Chemical compound CC1=CC(C=O)=CC(C)=N1 OFIMNDTVWZPKIN-UHFFFAOYSA-N 0.000 description 1
DDNZMSHBGPIXPX-UHFFFAOYSA-N 2,6-dimethylpyrimidine-4-carbaldehyde Chemical compound CC1=CC(C=O)=NC(C)=N1 DDNZMSHBGPIXPX-UHFFFAOYSA-N 0.000 description 1
RZBOMSOHMOVUES-UHFFFAOYSA-N 2-(2-chlorophenyl)ethanamine Chemical compound NCCC1=CC=CC=C1Cl RZBOMSOHMOVUES-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
UWVQOVPKNIPJCA-UHFFFAOYSA-N 2-(2-methylphenyl)-1h-phenanthro[9,10-d]imidazole Chemical compound CC1=CC=CC=C1C1=NC(C2=CC=CC=C2C2=CC=CC=C22)=C2N1 UWVQOVPKNIPJCA-UHFFFAOYSA-N 0.000 description 1
UBLVISZFNNSYBB-UHFFFAOYSA-N 2-(2-methylphenyl)prop-2-enenitrile Chemical compound CC1=CC=CC=C1C(=C)C#N UBLVISZFNNSYBB-UHFFFAOYSA-N 0.000 description 1
BIEFDNUEROKZRA-UHFFFAOYSA-N 2-(2-phenylethenyl)aniline Chemical group NC1=CC=CC=C1C=CC1=CC=CC=C1 BIEFDNUEROKZRA-UHFFFAOYSA-N 0.000 description 1
FHCUIVUFAWWYGB-UHFFFAOYSA-N 2-(4-aminobutyl)aniline Chemical compound NCCCCC1=CC=CC=C1N FHCUIVUFAWWYGB-UHFFFAOYSA-N 0.000 description 1
SWLMSOXBPVFLNF-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-pyridin-4-ylethanone Chemical compound C1=CC(F)=CC=C1CC(=O)C1=CC=NC=C1 SWLMSOXBPVFLNF-UHFFFAOYSA-N 0.000 description 1
OYFMPLLDEYKVOB-UHFFFAOYSA-N 2-(4-fluorophenyl)-3-(furan-2-ylmethyl)imidazo[4,5-b]quinoxaline Chemical compound C1=CC(F)=CC=C1C1=NC2=NC3=CC=CC=C3N=C2N1CC1=CC=CO1 OYFMPLLDEYKVOB-UHFFFAOYSA-N 0.000 description 1
MVXHLTSQEFSFJQ-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-pyridin-4-ylpyrimidine Chemical compound C1=CC(F)=CC=C1C1=NC=CC(C=2C=CN=CC=2)=N1 MVXHLTSQEFSFJQ-UHFFFAOYSA-N 0.000 description 1
XWDJFDVVJXYYCS-UHFFFAOYSA-N 2-(4-fluorophenyl)-6-pyridin-4-yl-1h-pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1C1=NC(C=2C=CN=CC=2)=CC(=O)N1 XWDJFDVVJXYYCS-UHFFFAOYSA-N 0.000 description 1
MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
ZKOAJJRKFOKTPB-UHFFFAOYSA-N 2-(4-fluorophenyl)ethyl acetate Chemical compound CC(=O)OCCC1=CC=C(F)C=C1 ZKOAJJRKFOKTPB-UHFFFAOYSA-N 0.000 description 1
LDZKLYOHYNPFLY-UHFFFAOYSA-N 2-(5-phenyl-1h-pyrazol-4-yl)pyridine Chemical class C1=NNC(C=2C=CC=CC=2)=C1C1=CC=CC=N1 LDZKLYOHYNPFLY-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
OGZSTQYGLHHIOK-UHFFFAOYSA-N 2-amino-3-(2-fluorophenyl)propanamide Chemical compound NC(=O)C(N)CC1=CC=CC=C1F OGZSTQYGLHHIOK-UHFFFAOYSA-N 0.000 description 1
SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
QMKZZQPPJRWDED-UHFFFAOYSA-N 2-aminopyridine-4-carboxylic acid Chemical compound NC1=CC(C(O)=O)=CC=N1 QMKZZQPPJRWDED-UHFFFAOYSA-N 0.000 description 1
QXCOHSRHFCHCHN-UHFFFAOYSA-N 2-chloropyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(Cl)=C1 QXCOHSRHFCHCHN-UHFFFAOYSA-N 0.000 description 1
TWWCBLSUGOSDIY-UHFFFAOYSA-N 2-ethyl-1,1-dimethylhydrazine Chemical compound CCNN(C)C TWWCBLSUGOSDIY-UHFFFAOYSA-N 0.000 description 1
CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
UKCIGJJDGDAIEU-UHFFFAOYSA-N 2-methoxy-n,n-dimethylpropan-2-amine Chemical compound COC(C)(C)N(C)C UKCIGJJDGDAIEU-UHFFFAOYSA-N 0.000 description 1
239000001431 2-methylbenzaldehyde Substances 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
BXHGNAADUUXBKK-UHFFFAOYSA-N 2-methylpyrimidine-4-carbaldehyde Chemical compound CC1=NC=CC(C=O)=N1 BXHGNAADUUXBKK-UHFFFAOYSA-N 0.000 description 1
HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 1
ZXTHWIZHGLNEPG-UHFFFAOYSA-N 2-phenyl-4,5-dihydro-1,3-oxazole Chemical compound O1CCN=C1C1=CC=CC=C1 ZXTHWIZHGLNEPG-UHFFFAOYSA-N 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
CKEKULWTUGAESO-UHFFFAOYSA-N 2-phenylpropylhydrazine Chemical compound NNCC(C)C1=CC=CC=C1 CKEKULWTUGAESO-UHFFFAOYSA-N 0.000 description 1
WECZBIRUFSBADT-UHFFFAOYSA-N 2-pyridin-4-ylpyrimidine hydrochloride Chemical compound Cl.N1=CC=C(C=C1)C1=NC=CC=N1 WECZBIRUFSBADT-UHFFFAOYSA-N 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
LUYOTDGHRZDHDB-UHFFFAOYSA-N 3-(2-methylphenyl)propan-1-amine Chemical compound CC1=CC=CC=C1CCCN LUYOTDGHRZDHDB-UHFFFAOYSA-N 0.000 description 1
LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
AQKKRXMVSOXABZ-UHFFFAOYSA-N 3-anilinopropanoic acid Chemical compound OC(=O)CCNC1=CC=CC=C1 AQKKRXMVSOXABZ-UHFFFAOYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 1
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
MVKDNXIKAWKCCS-UHFFFAOYSA-N 3-methyl-1h-pyridin-2-one Chemical compound CC1=CC=CN=C1O MVKDNXIKAWKCCS-UHFFFAOYSA-N 0.000 description 1
VDAPLJNLRIKFQC-UHFFFAOYSA-N 3-pyridin-4-ylpropanal Chemical compound O=CCCC1=CC=NC=C1 VDAPLJNLRIKFQC-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
AHOIVVKRHCTFHO-UHFFFAOYSA-N 4-[4-(2-fluorophenyl)piperazin-1-yl]-1-phenylpyrazolo[3,4-d]pyrimidine Chemical compound FC1=CC=CC=C1N1CCN(C=2C=3C=NN(C=3N=CN=2)C=2C=CC=CC=2)CC1 AHOIVVKRHCTFHO-UHFFFAOYSA-N 0.000 description 1
KPABRDGBGDVPCC-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-4-pyridin-4-ylpyrimidin-2-yl]morpholine Chemical compound C1=CC(F)=CC=C1C1=CN=C(N2CCOCC2)N=C1C1=CC=NC=C1 KPABRDGBGDVPCC-UHFFFAOYSA-N 0.000 description 1
XIBPCLQLEGQADN-UHFFFAOYSA-N 4-acetyloxy-4-oxobutanoic acid Chemical compound CC(=O)OC(=O)CCC(O)=O XIBPCLQLEGQADN-UHFFFAOYSA-N 0.000 description 1
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical group COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
VGENLLAEDBMNSC-UHFFFAOYSA-N 4-methyl-2-nitropyridine Chemical compound CC1=CC=NC([N+]([O-])=O)=C1 VGENLLAEDBMNSC-UHFFFAOYSA-N 0.000 description 1
UBGSMHJOMIMVAW-UHFFFAOYSA-N 4-methylpyrimidine-2-carbaldehyde Chemical compound CC1=CC=NC(C=O)=N1 UBGSMHJOMIMVAW-UHFFFAOYSA-N 0.000 description 1
MDTMSQWCCLSYFA-UHFFFAOYSA-N 5-(4-fluorophenyl)-2-(3-phenylpropyl)-6-pyridin-4-ylpyrimidin-4-amine Chemical compound FC1=CC=C(C=C1)C=1C(=NC(=NC=1N)CCCC1=CC=CC=C1)C1=CC=NC=C1 MDTMSQWCCLSYFA-UHFFFAOYSA-N 0.000 description 1
DAMZFIYOEBDWLN-UHFFFAOYSA-N 5-(4-fluorophenyl)-2-(3-phenylpropylamino)-6-pyridin-4-yl-1h-pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1C(C(N1)=O)=C(C=2C=CN=CC=2)N=C1NCCCC1=CC=CC=C1 DAMZFIYOEBDWLN-UHFFFAOYSA-N 0.000 description 1
CFGHSRDNTILIGJ-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-pyridin-4-yl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)NC(=S)NC1=O CFGHSRDNTILIGJ-UHFFFAOYSA-N 0.000 description 1
QCANDZGZNIXHRH-UHFFFAOYSA-N 5-(4-fluorophenyl)-n-(3-phenylpropyl)-4-pyridin-4-ylpyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1C(C(=N1)C=2C=CN=CC=2)=CN=C1NCCCC1=CC=CC=C1 QCANDZGZNIXHRH-UHFFFAOYSA-N 0.000 description 1
BGUNEQJBAXZMFT-UHFFFAOYSA-N 5-(4-fluorophenyl)-n-[2-(2-fluorophenyl)ethyl]-4-pyridin-4-ylpyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1C(C(=N1)C=2C=CN=CC=2)=CN=C1NCCC1=CC=CC=C1F BGUNEQJBAXZMFT-UHFFFAOYSA-N 0.000 description 1
DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
OSBSXTGABLIDRX-UHFFFAOYSA-N 5-methylidenecyclohexa-1,3-diene Chemical compound C=C1CC=CC=C1 OSBSXTGABLIDRX-UHFFFAOYSA-N 0.000 description 1
LQMPUMZAMJWOIC-UHFFFAOYSA-N 6-bromo-3-(5-chloro-2-ethylsulfonylanilino)-7-[(4-cyclopentylpiperazin-1-yl)methyl]quinazolin-4-one Chemical compound BrC=1C=C2C(N(C=NC2=CC=1CN1CCN(CC1)C1CCCC1)NC1=C(C=CC(=C1)Cl)S(=O)(=O)CC)=O LQMPUMZAMJWOIC-UHFFFAOYSA-N 0.000 description 1
YXFLIXMGJXYOAN-UHFFFAOYSA-N 6-methylidenecyclohex-3-ene-1,2-dione Chemical compound C=C1CC=CC(=O)C1=O YXFLIXMGJXYOAN-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
PZASAAIJIFDWSB-CKPDSHCKSA-N 8-[(1S)-1-[8-(trifluoromethyl)-7-[4-(trifluoromethyl)cyclohexyl]oxynaphthalen-2-yl]ethyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound FC(F)(F)C=1C2=CC([C@@H](N3C4CCC3CC(C4)C(O)=O)C)=CC=C2C=CC=1OC1CCC(C(F)(F)F)CC1 PZASAAIJIFDWSB-CKPDSHCKSA-N 0.000 description 1
USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
YDXRPPDCHGHWMY-UHFFFAOYSA-N 9-pyridin-2-ylfluoren-9-ol Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(O)C1=CC=CC=N1 YDXRPPDCHGHWMY-UHFFFAOYSA-N 0.000 description 1
WGOQTNXYTDSHRT-UHFFFAOYSA-N 9h-fluorene-1-carbonitrile Chemical group C1C2=CC=CC=C2C2=C1C(C#N)=CC=C2 WGOQTNXYTDSHRT-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
241000234282 Allium Species 0.000 description 1
229910000951 Aluminide Inorganic materials 0.000 description 1
244000024893 Amaranthus tricolor Species 0.000 description 1
235000014748 Amaranthus tricolor Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
LIXPIEPRDFPNIG-UHFFFAOYSA-N C(C)OC(C(C(=O)O)(OCC)C1=CC=CC=2C3=CC=CC=C3CC12)C(=O)O Chemical compound C(C)OC(C(C(=O)O)(OCC)C1=CC=CC=2C3=CC=CC=C3CC12)C(=O)O LIXPIEPRDFPNIG-UHFFFAOYSA-N 0.000 description 1
125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
NAPGWNWMEDJYJP-UHFFFAOYSA-N C=1CCC=C2OC3=CC=CC=C3C(C=12)=O Chemical compound C=1CCC=C2OC3=CC=CC=C3C(C=12)=O NAPGWNWMEDJYJP-UHFFFAOYSA-N 0.000 description 1
KIJJNPNLPXWZTQ-UHFFFAOYSA-N CN(C)CC[S] Chemical compound CN(C)CC[S] KIJJNPNLPXWZTQ-UHFFFAOYSA-N 0.000 description 1
101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000283707 Capra Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
235000007516 Chrysanthemum Nutrition 0.000 description 1
240000005250 Chrysanthemum indicum Species 0.000 description 1
241000723346 Cinnamomum camphora Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
229930182832 D-phenylalanine Natural products 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
KULUZCGVKXGWHU-UHFFFAOYSA-N FC1=CC=C(C=C1)C=1C(=NC(=NC1)NC1=C(C=CC=C1)OC)C1=CC=NC=C1.CC1=C(C(=CC=C1)C)NC1=NC=C(C(=N1)C1=CC=NC=C1)C1=CC=C(C=C1)F Chemical compound FC1=CC=C(C=C1)C=1C(=NC(=NC1)NC1=C(C=CC=C1)OC)C1=CC=NC=C1.CC1=C(C(=CC=C1)C)NC1=NC=C(C(=N1)C1=CC=NC=C1)C1=CC=C(C=C1)F KULUZCGVKXGWHU-UHFFFAOYSA-N 0.000 description 1
YTIBAIKOKDODRR-UHFFFAOYSA-N FC1=CC=C(C=C1)CCC1=CC=CC=2C3=CC=CC=C3CC12 Chemical compound FC1=CC=C(C=C1)CCC1=CC=CC=2C3=CC=CC=C3CC12 YTIBAIKOKDODRR-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Chemical class 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
108010068370 Glutens Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920000084 Gum arabic Chemical class 0.000 description 1
206010020164 HIV infection CDC Group III Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
208000004454 Hyperalgesia Diseases 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
206010023232 Joint swelling Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
AEQQYHLPLFYBPA-UHFFFAOYSA-N N1C(=NC=C1)CCCC=1C(=NC(=NC1)N)C1=CC=NC=C1 Chemical compound N1C(=NC=C1)CCCC=1C(=NC(=NC1)N)C1=CC=NC=C1 AEQQYHLPLFYBPA-UHFFFAOYSA-N 0.000 description 1
101100258328 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) crc-2 gene Proteins 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920002230 Pectic acid Polymers 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
208000005374 Poisoning Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
241000219492 Quercus Species 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
229910006069 SO3H Inorganic materials 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical group OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
229910052776 Thorium Inorganic materials 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
235000010725 Vigna aconitifolia Nutrition 0.000 description 1
235000009754 Vitis X bourquina Nutrition 0.000 description 1
235000012333 Vitis X labruscana Nutrition 0.000 description 1
240000006365 Vitis vinifera Species 0.000 description 1
235000014787 Vitis vinifera Nutrition 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
RKSZCOGKXZGLAI-UHFFFAOYSA-N ac1lbdqa Chemical group [SiH3]N[SiH3] RKSZCOGKXZGLAI-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Chemical class 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000008062 acetophenones Chemical class 0.000 description 1
TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
229920000180 alkyd Polymers 0.000 description 1
125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
150000008052 alkyl sulfonates Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
AEMOLEFTQBMNLQ-BKBMJHBISA-M alpha-D-galacturonate Chemical compound O[C@H]1O[C@H](C([O-])=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-M 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001414 amino alcohols Chemical class 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
150000003937 benzamidines Chemical class 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
AZFMSHWYDZIRNV-UHFFFAOYSA-N benzenesulfonic acid;pyridine Chemical compound C1=CC=NC=C1.OS(=O)(=O)C1=CC=CC=C1 AZFMSHWYDZIRNV-UHFFFAOYSA-N 0.000 description 1
FHCIILYMWWRNIZ-UHFFFAOYSA-N benzhydryl(chloro)silane Chemical compound C=1C=CC=CC=1C([SiH2]Cl)C1=CC=CC=C1 FHCIILYMWWRNIZ-UHFFFAOYSA-N 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
229940093265 berberine Drugs 0.000 description 1
QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
125000005998 bromoethyl group Chemical group 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
YVUFJNPICCDBFS-UHFFFAOYSA-N butan-2-one;prop-1-ene Chemical compound CC=C.CCC(C)=O YVUFJNPICCDBFS-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000006309 butyl amino group Chemical group 0.000 description 1
MXOSTENCGSDMRE-UHFFFAOYSA-N butyl-chloro-dimethylsilane Chemical compound CCCC[Si](C)(C)Cl MXOSTENCGSDMRE-UHFFFAOYSA-N 0.000 description 1
HQABUPZFAYXKJW-UHFFFAOYSA-O butylazanium Chemical class CCCC[NH3+] HQABUPZFAYXKJW-UHFFFAOYSA-O 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
229960000846 camphor Drugs 0.000 description 1
229930008380 camphor Natural products 0.000 description 1
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
238000010531 catalytic reduction reaction Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000003915 cell function Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
210000004720 cerebrum Anatomy 0.000 description 1
125000003901 ceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
KWYZNESIGBQHJK-UHFFFAOYSA-N chloro-dimethyl-phenylsilane Chemical compound C[Si](C)(Cl)C1=CC=CC=C1 KWYZNESIGBQHJK-UHFFFAOYSA-N 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000013066 combination product Substances 0.000 description 1
229940127555 combination product Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000006880 cross-coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000004802 cyanophenyl group Chemical group 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
238000010908 decantation Methods 0.000 description 1
238000006298 dechlorination reaction Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical group CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
229960003887 dichlorophen Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
125000005675 difluoroethenyl group Chemical group [H]C(*)=C(F)F 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical group [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000009429 distress Effects 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002081 enamines Chemical class 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
QGBMSFLTRRZTGI-UHFFFAOYSA-N ethyl(dimethyl)silane Chemical compound CC[SiH](C)C QGBMSFLTRRZTGI-UHFFFAOYSA-N 0.000 description 1
WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 1
125000006125 ethylsulfonyl group Chemical group 0.000 description 1
125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
YLQWCDOCJODRMT-UHFFFAOYSA-N fluoren-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C2=C1 YLQWCDOCJODRMT-UHFFFAOYSA-N 0.000 description 1
125000005567 fluorenylene group Chemical group 0.000 description 1
125000004175 fluorobenzyl group Chemical group 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Chemical class 0.000 description 1
229920000159 gelatin Chemical class 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
235000021312 gluten Nutrition 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
150000002332 glycine derivatives Chemical class 0.000 description 1
108010083391 glycinin Proteins 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
159000000011 group IA salts Chemical class 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000012771 household material Substances 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
125000005597 hydrazone group Chemical group 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Chemical group O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000006362 insulin response pathway Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000019189 interleukin-1 beta production Effects 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000013521 mastic Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910000000 metal hydroxide Inorganic materials 0.000 description 1
150000004692 metal hydroxides Chemical class 0.000 description 1
ORAKNQSHWMHCEY-UHFFFAOYSA-N methyl 2-pyridin-2-ylacetate Chemical compound COC(=O)CC1=CC=CC=N1 ORAKNQSHWMHCEY-UHFFFAOYSA-N 0.000 description 1
229940017219 methyl propionate Drugs 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
210000003657 middle cerebral artery Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
CSGVXMPCKSSCSY-UHFFFAOYSA-N n'-(4-fluorophenyl)ethane-1,2-diamine Chemical compound NCCNC1=CC=C(F)C=C1 CSGVXMPCKSSCSY-UHFFFAOYSA-N 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
IANQVURMLZDWCH-UHFFFAOYSA-N n,5-bis(4-fluorophenyl)-4-pyridin-4-ylpyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1NC(N=C1C=2C=CN=CC=2)=NC=C1C1=CC=C(F)C=C1 IANQVURMLZDWCH-UHFFFAOYSA-N 0.000 description 1
HXRAMSFGUAOAJR-UHFFFAOYSA-N n,n,n',n'-tetramethyl-1-[(2-methylpropan-2-yl)oxy]methanediamine Chemical compound CN(C)C(N(C)C)OC(C)(C)C HXRAMSFGUAOAJR-UHFFFAOYSA-N 0.000 description 1
VCQVIPNKYJBLLL-UHFFFAOYSA-N n-(2,6-dichlorophenyl)-5-(4-fluorophenyl)-4-pyridin-4-ylpyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1C(C(=N1)C=2C=CN=CC=2)=CN=C1NC1=C(Cl)C=CC=C1Cl VCQVIPNKYJBLLL-UHFFFAOYSA-N 0.000 description 1
125000006126 n-butyl sulfonyl group Chemical group 0.000 description 1
125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
125000004706 n-propylthio group Chemical group C(CC)S* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
208000008798 osteoma Diseases 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000005429 oxyalkyl group Chemical group 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
238000012856 packing Methods 0.000 description 1
MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
230000004053 pancreatic β cell dysfunction Effects 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
125000005561 phenanthryl group Chemical group 0.000 description 1
150000007965 phenolic acids Chemical class 0.000 description 1
125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
125000006247 phenyl propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229960003424 phenylacetic acid Drugs 0.000 description 1
239000003279 phenylacetic acid Substances 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
MLCHBQKMVKNBOV-UHFFFAOYSA-N phenylphosphinic acid Chemical group OP(=O)C1=CC=CC=C1 MLCHBQKMVKNBOV-UHFFFAOYSA-N 0.000 description 1
XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
235000017807 phytochemicals Nutrition 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
229930000223 plant secondary metabolite Natural products 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000164 protein isolation Methods 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 1
ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
235000008160 pyridoxine Nutrition 0.000 description 1
239000011677 pyridoxine Substances 0.000 description 1
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
IDXKTTNFXPPXJY-UHFFFAOYSA-N pyrimidin-1-ium;chloride Chemical compound Cl.C1=CN=CN=C1 IDXKTTNFXPPXJY-UHFFFAOYSA-N 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
RONWGALEIBILOG-VMJVVOMYSA-N quinine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 RONWGALEIBILOG-VMJVVOMYSA-N 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
239000012217 radiopharmaceutical Substances 0.000 description 1
229940121896 radiopharmaceutical Drugs 0.000 description 1
230000002799 radiopharmaceutical effect Effects 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
230000035807 sensation Effects 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229910000077 silane Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000000779 smoke Substances 0.000 description 1
239000000661 sodium alginate Chemical class 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
229910001948 sodium oxide Inorganic materials 0.000 description 1
RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
229910052979 sodium sulfide Inorganic materials 0.000 description 1
GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
235000021286 stilbenes Nutrition 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000000859 sublimation Methods 0.000 description 1
230000008022 sublimation Effects 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229910052715 tantalum Inorganic materials 0.000 description 1
GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
125000004001 thioalkyl group Chemical group 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
150000003585 thioureas Chemical class 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
238000004448 titration Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
125000000165 tricyclic carbocycle group Chemical group 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
COHOGNZHAUOXPA-UHFFFAOYSA-N trimethyl(phenyl)stannane Chemical compound C[Sn](C)(C)C1=CC=CC=C1 COHOGNZHAUOXPA-UHFFFAOYSA-N 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000005533 tritiation Methods 0.000 description 1
238000001665 trituration Methods 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
OBYIEPMKXIBQEV-UHFFFAOYSA-N undecyl hydrogen sulfate Chemical compound CCCCCCCCCCCOS(O)(=O)=O OBYIEPMKXIBQEV-UHFFFAOYSA-N 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
125000005289 uranyl group Chemical group 0.000 description 1
HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1
XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc oxide Inorganic materials [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Virology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)

TW086118244A 1996-12-05 1997-12-04 Substituted pyrimidine compounds and pharmaceutical composition comprising same TW520362B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3212896P	1996-12-05	1996-12-05
US5095097P	1997-06-13	1997-06-13

Publications (1)

Publication Number	Publication Date
TW520362B true TW520362B (en)	2003-02-11

Family

ID=26708010

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW086118244A TW520362B (en)	1996-12-05	1997-12-04	Substituted pyrimidine compounds and pharmaceutical composition comprising same

Country Status (4)

Country	Link
JP (1)	JP2002514195A (fr)
AR (1)	AR038955A1 (fr)
TW (1)	TW520362B (fr)
WO (1)	WO1998024782A2 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6613942B1 (en)	1997-07-01	2003-09-02	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
ATE274510T1 (de) *	1998-06-19	2004-09-15	Chiron Corp	Glycogen synthase kinase 3 inhibitoren
TWI241298B (en) *	1998-09-25	2005-10-11	Mitsubishi Chem Corp	Pyrimidone derivatives
AU1909200A (en)	1998-11-04	2000-05-22	Smithkline Beecham Corporation	Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6350744B1 (en)	1998-11-20	2002-02-26	Merck & Co., Inc.	Compounds having cytokine inhibitory activity
JP2002534385A (ja)	1999-01-08	2002-10-15	スミスクライン・ビーチャム・コーポレイション	新規化合物
US6503949B1 (en)	1999-05-17	2003-01-07	Noro Nordisk A/S	Glucagon antagonists/inverse agonists
US7122666B2 (en)	1999-07-21	2006-10-17	Sankyo Company, Limited	Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
GB9927844D0 (en)	1999-11-26	2000-01-26	Glaxo Group Ltd	Chemical compounds
DE60043397D1 (de) *	1999-12-28	2010-01-07	Pharmacopeia Inc	Cytokine, insbesondere tnf-alpha, hemmer
US6906067B2 (en)	1999-12-28	2005-06-14	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of TNF-α expression
GB0003224D0 (en)	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds
EP1136483A1 (fr) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	Dérivés de 2-[pipérazinyl]pyrimidinone
EP1136485A1 (fr) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	Dérivés d' aminophénylpyrimidinone
EP1136486A1 (fr) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	Dérivés de 2-(indanylamino)pyrimidinone et de 2-(tétrahydronaphtalénylamino)pyrimidione
EP1136493A1 (fr) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	Dérivés de 2-(thienopyridinyl)pyrimidones, 2-(furopyridinyl)pyrimidones, 2-(isoquinolinyl)pyrimidones, 2-(pyridoindolyl)pyrimidones et 2-(benzofuropyridinyl)pyrimidones
EP1136491A1 (fr) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	Dérivés de 2-[(hétéroaryl)alkylamino]pyrimidinones
AU2001262150A1 (en) *	2000-03-23	2001-10-03	Mitsubishi Pharma Corporation	2-(nitrogen-heterocyclic)pyrimidone derivatives
EP1136484A1 (fr) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	Dérivés de 2-(arylalkylamino)pyrimidine
EP1136482A1 (fr) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	Dérivés de 2-amino-3-(alkyl)-pyrimidone comme inhibiteurs de GSK3bêta
EP1136099A1 (fr) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	Dérivés de 2-(indolylalkylamino)pyridone comme inhibiteurs de GSK3bêta
EP1136489A1 (fr) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	Dérivés de 2-[pipéridinyl]pyrimidinone
WO2001070727A1 (fr) *	2000-03-23	2001-09-27	Sanofi-Synthelabo	Derives de 2-(arylalkylamino)pyrimidone et derives de 2-(heteroarylalkylamino)pyrimidone
US7189717B2 (en)	2000-04-26	2007-03-13	Eisai Co., Ltd.	Medicinal compositions promoting bowel movement
KR100840816B1 (ko) *	2000-05-12	2008-06-23	젠자임 코포레이션	ＴＮＦ-α시그널링의 조절물질
US6562807B2 (en)	2000-06-23	2003-05-13	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
GB0021494D0 (en) *	2000-09-01	2000-10-18	Glaxo Group Ltd	Chemical comkpounds
WO2002020495A2 (fr) *	2000-09-06	2002-03-14	Chiron Corporation	Inhibiteurs de glycogene-synthase kinase 3
US6670362B2 (en)	2000-09-20	2003-12-30	Pfizer Inc.	Pyridazine endothelin antagonists
AU2002223500A1 (en)	2000-11-17	2002-05-27	Novo-Nordisk A/S	Glucagon antagonists/inverse agonists
US6706744B2 (en)	2000-11-17	2004-03-16	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
US6821960B2 (en)	2000-11-17	2004-11-23	Noyo Nordisk Pharmaceuticals, Inc.	Glucagon antagonists/inverse agonists
GB0112810D0 (en) *	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0112802D0 (en)	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0119477D0 (en) *	2001-08-09	2001-10-03	Glaxo Group Ltd	Pyrimidine derivatives
IL160700A0 (en)	2001-09-21	2004-08-31	Mitsubishi Pharma Corp	3-substituted-4-pyrimidone derivatives
CN101274928A (zh) *	2001-09-21	2008-10-01	三菱制药株式会社	3-取代的-4-嘧啶酮衍生物
IL160701A0 (en)	2001-09-21	2004-08-31	Mitsubishi Pharma Corp	3-substituted-4-pyrimidone derivatives
TWI330183B (fr)	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
TWI301834B (en)	2001-10-22	2008-10-11	Eisai R&D Man Co Ltd	Pyrimidone compound and pharmaceutical composition including the same
US6921762B2 (en)	2001-11-16	2005-07-26	Amgen Inc.	Substituted indolizine-like compounds and methods of use
US6762318B2 (en)	2001-12-03	2004-07-13	Novo Nordisk A/S	Glucagon antagonists
US6881746B2 (en)	2001-12-03	2005-04-19	Novo Nordick A/S	Glucagon antagonists/inverse agonists
TW200302728A (en)	2002-02-01	2003-08-16	Novartis Ag	Substituted amines as IgE inhibitors
US6855709B2 (en)	2002-02-22	2005-02-15	Pharmacia & Upjohn Company	Pyridyl sulfone derivatives
US7232827B2 (en) *	2002-02-28	2007-06-19	Sanofi-Aventis	Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
US20030225075A1 (en) *	2002-04-10	2003-12-04	Orchid Chemicals & Pharmaceuticals Limited	Novel pyrimidone derivatives
AU2003234628B2 (en) *	2002-05-21	2007-08-23	Amgen Inc.	Substituted heterocyclic compounds and methods of use
WO2004004725A2 (fr)	2002-07-09	2004-01-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Nouvelles compositions pharmaceutiques a base de nouveaux anticholinergiques et d'inhibiteurs de la kinase p38
ATE325115T1 (de)	2002-08-19	2006-06-15	Glaxo Group Ltd	Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
CN1726209B (zh)	2002-12-16	2011-04-13	三菱制药株式会社	3-取代的-4-嘧啶酮衍生物
WO2004069846A1 (fr) *	2003-02-06	2004-08-19	Basf Aktiengesellschaft	Pyrimidines, leur procede de production et leur utilisation
TWI357408B (en)	2003-03-26	2012-02-01	Mitsubishi Tanabe Pharma Corp	3-substituted-4-pyrimidone derivatives
CA2531619A1 (fr) *	2003-07-16	2005-01-27	Neurogen Corporation	Analogues de biaryl piperazinyl-pyridine
WO2005039485A2 (fr) *	2003-08-13	2005-05-06	Chiron Corporation	Inhibiteurs de gsk-3 et utilisations
CA2535644A1 (fr) *	2003-08-20	2005-03-03	Amgen Inc.	Derives de pyrimdinone substitues et leurs procedes d'utilisation
GB0323137D0 (en)	2003-10-03	2003-11-05	Chang Lisa C W	2,4,6- Trisubstituted pyrimidines and their different uses
CA2562244A1 (fr) *	2004-04-07	2005-10-27	Takeda Pharmaceutical Company Limited	Composes cycliques
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
MY145822A (en)	2004-08-13	2012-04-30	Neurogen Corp	Substituted biaryl piperazinyl-pyridine analogues
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP5118029B2 (ja)	2005-06-14	2013-01-16	タイゲンバイオテクノロジーカンパニー，リミテッド	ピリミジン化合物
US8193206B2 (en)	2005-06-14	2012-06-05	Taigen Biotechnology Co., Ltd.	Pyrimidine compounds
ES2270715B1 (es)	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
WO2007022964A2 (fr)	2005-08-24	2007-03-01	Abbott Gmbh & Co. Kg	Composes guanidine a substitution hetaryl et utilisation en tant que partenaires de liaison pour des recepteurs de 5-ht5
ES2274712B1 (es)	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
JP2010505957A (ja)	2006-10-10	2010-02-25	アムゲンインコーポレイティッド	糖尿病に対して使用されるｎ−アリールピラゾール化合物
EP1992344A1 (fr)	2007-05-18	2008-11-19	Institut Curie	P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
CA2694275A1 (fr) *	2007-07-26	2009-01-29	Novartis Ag	Composes organiques
EA019289B1 (ru)	2008-04-21	2014-02-28	Тайджен Байотекнолоджи Ко., Лтд.	Производные аминопиридина, аминопиримидина и амино-1,3,5-триазина
WO2010056847A2 (fr)	2008-11-13	2010-05-20	Taigen Biotechnology Co., Ltd.	Formule lyophilisée
NZ734152A (en)	2010-10-18	2019-03-29	Cerenis Therapeutics Holding Sa	Compounds, compositions and methods useful for cholesterol mobilisation
GB201106829D0 (en)	2011-04-21	2011-06-01	Proximagen Ltd	Heterocyclic compounds
BR112013016033A2 (pt)	2010-12-23	2018-06-05	Pfizer	moduladores do receptor de glucagon
ES2597972T3 (es)	2011-02-08	2017-01-24	Pfizer Inc	Modulador del receptor de glucagón
ES2550345T3 (es)	2011-07-22	2015-11-06	Pfizer Inc.	Moduladores del receptor de quinolinilglucagón
EP2776405A1 (fr)	2011-11-11	2014-09-17	Pfizer Inc	2-thiopyrimidinones
JP6454348B2 (ja)	2013-12-19	2019-01-16	サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅＬａｋｅＰｈａｒｍａＣｏ．，Ｌｔｄ．	窒素複素環誘導体およびその医薬品への応用
TWI651310B (zh) *	2014-02-20	2019-02-21	日商日本煙草產業股份有限公司	三化合物及其醫藥用途
PE20180503A1 (es)	2015-05-05	2018-03-09	Pfizer	2-tiopirimidinonas
MX375283B (es)	2015-08-17	2025-03-06	Japan Tobacco Inc	Compuesto hidroxitriazina y su uso medico.
JP6817952B2 (ja) *	2015-10-29	2021-01-20	あすか製薬株式会社	ピリミジン誘導体
RU2765154C2 (ru) *	2015-11-04	2022-01-26	Мерк Патент Гмбх	Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
PL3377484T3 (pl) *	2015-11-17	2024-04-08	Merck Patent Gmbh	Metody dla terapii stwardnienia rozsianego z użyciem związków pirymidynowych i pirydynowych z aktywnością inhibitorową dla btk
TW201811766A (zh)	2016-08-29	2018-04-01	瑞士商諾華公司	N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
PH12022551138A1 (en) *	2019-11-12	2023-07-17	Genzyme Corp	6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
JP2025541771A (ja)	2022-12-02	2025-12-23	ニューモラセラピューティクスインコーポレイテッド	神経障害を処置する方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1271116B (de) *	1965-05-04	1968-06-27	Bayer Ag	Verfahren zur Herstellung von 4-Hydroxypyrimidinen
BE759176A (fr) *	1969-11-20	1971-05-19	Sandoz Sa	Derives de la pyrimidine, leur preparation et medicaments contenant cesderives
US4438117A (en) *	1980-09-03	1984-03-20	E. I. Du Pont De Nemours And Company	2-Substituted thio-4,5-diarylpyrimidines
DE3319843A1 (de) *	1983-06-01	1984-12-06	Ali-Akbar Dipl.-Chem. Dr. 4300 Mülheim Pourzal	Verfahren zur herstellung von pyrimidinen aus nitrilen und alkinen
US4500533A (en) *	1983-06-22	1985-02-19	Eli Lilly And Company	2,4,5-Triaryl pyrimidines and a method of treating pain, fever, thrombosis, inflammation and arthritis
US5077142A (en) *	1989-04-20	1991-12-31	Ricoh Company, Ltd.	Electroluminescent devices
US5620999A (en) *	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
AU702146B2 (en) *	1995-10-06	1999-02-11	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
WO1997016442A1 (fr) *	1995-10-31	1997-05-09	Merck & Co., Inc.	Pyrroles de pyridyle substitues, compositions contenant de tels composes et mode d'utilisation
EP0888335A4 (fr) *	1996-03-13	2002-01-02	Smithkline Beecham Corp	Nouveaux composes de pyrimidine utiles dans le traitement de maladies a mediation cytokine

1997
- 1997-12-04 TW TW086118244A patent/TW520362B/zh not_active IP Right Cessation
- 1997-12-04 JP JP52585098A patent/JP2002514195A/ja active Pending
- 1997-12-04 WO PCT/US1997/022390 patent/WO1998024782A2/fr not_active Ceased
- 1997-12-04 AR ARP970105716A patent/AR038955A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1998024782A3 (fr)	1998-08-27
AR038955A1 (es)	2005-02-02
WO1998024782A2 (fr)	1998-06-11
JP2002514195A (ja)	2002-05-14

Legal Events

Date	Code	Title	Description
2003-06-09	GD4A	Issue of patent certificate for granted invention patent
2009-11-21	MM4A	Annulment or lapse of patent due to non-payment of fees

Publication	Publication Date	Title
TW520362B (en)	2003-02-11	Substituted pyrimidine compounds and pharmaceutical composition comprising same
CN1328277C (zh)	2007-07-25	取代的嘧啶酮和吡啶酮化合物和它们的应用
US10596163B2 (en)	2020-03-24	Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides
US6420385B1 (en)	2002-07-16	Substituted pyrimidinone and pyridone compounds and methods of use
US6610698B2 (en)	2003-08-26	Substituted pyrimidine compounds and methods of use
AU2004226165C1 (en)	2008-07-03	Pyrimidin-4-one derivatives and their use as p38 kinase modulators
RU2196139C2 (ru)	2003-01-10	1,4,5-тризамещенные производные имидазола, способы их получения и фармацевтическая композиция на их основе
US20060069110A1 (en)	2006-03-30	Substituted heterocyclic compounds and methods of use
JP2001506980A (ja)	2001-05-29	アリールおよびヘテロアリール置換縮合ピロール抗炎症剤
JP2002509537A (ja)	2002-03-26	新規なシクロアルキル置換イミダゾール化合物
JPH11513017A (ja)	1999-11-09	イミダゾール化合物
JP2001526263A (ja)	2001-12-18	置換ピリジン及びピリダジン化合物並びにそれらの医薬的使用
CZ11996A3 (en)	1996-10-16	Tri-substituted imidazoles, process of their preparation, intermediates of the process, pharmaceutical preparation and the use of the compounds for various therapeutical applications
JP2008502628A (ja)	2008-01-31	ピリダジン−３（２ｈ）−オン誘導体およびｐｄｅ４の阻害剤としてのそれらの使用
CZ20012494A3 (cs)	2001-10-17	Substituované 2-aryl-3-(heteroaryl)-imidazo[1,2-a]Pyrimidiny, způsob přípravy těchto sloučenin a farmaceutické kompozice obsahující tyto sloučeniny
AU733877B2 (en)	2001-05-31	Substituted pyrimidine compounds and their use
MXPA99005168A (en)	2000-04-24	Substituted pyrimidine compounds and their use
EP1314732A2 (fr)	2003-05-28	Composés de pyrimidine substitués et leur utilisation
KR20000069328A (ko)	2000-11-25	치환된 피리미딘 화합물과 그것의 용도
AU8142901A (en)	2002-01-03	Substituted pyrimidinone and pyridone compounds and methods of use